Table of Contents

company-logo

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Y-mAbs Therapeutics Dividend Announcement

• Y-mAbs Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Y-mAbs Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Y-mAbs Therapeutics Dividend History

Y-mAbs Therapeutics Dividend Yield

Y-mAbs Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Y-mAbs Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Y-mAbs Therapeutics Financial Ratios

P/E ratio-27.81
PEG ratio1.45
P/B ratio7.18
ROE-24.61%
Payout ratio0.00%
Current ratio3.92
Quick ratio3.54
Cash Ratio2.69

Y-mAbs Therapeutics Dividend FAQ

Does Y-mAbs Therapeutics stock pay dividends?
Y-mAbs Therapeutics does not currently pay dividends to its shareholders.
Has Y-mAbs Therapeutics ever paid a dividend?
No, Y-mAbs Therapeutics has no a history of paying dividends to its shareholders. Y-mAbs Therapeutics is not known for its dividend payments.
Why doesn't Y-mAbs Therapeutics pay dividends?
There are several potential reasons why Y-mAbs Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Y-mAbs Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Y-mAbs Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Y-mAbs Therapeutics a dividend aristocrat?
Y-mAbs Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Y-mAbs Therapeutics a dividend king?
Y-mAbs Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Y-mAbs Therapeutics a dividend stock?
No, Y-mAbs Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Y-mAbs Therapeutics stocks?
To buy Y-mAbs Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Y-mAbs Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.